Joint offering seeks to embed trust and transparency into the lifecycle of tokenized assets, aligning sustainability metrics with the next generation of digital-market infrastructure. Joint offering seeks to embed trust and transparency into the lifecycle of tokenized assets, aligning sustainability metrics with the next generation of digital-market infrastructure.

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS®) taking place from December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.

Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET

CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.

The biggest thing impacting the EV maker's shares this week highlights its shift to being an AI play.

BCE Inc. is poised for a rebound after a significant dividend cut, improved cash flow, and a strategic U.S. expansion via Ziply Fiber. BCE now retains ~$500 million more quarterly, enabling debt reduction, balance sheet repair, and supporting a sustainable dividend yield. Valuation metrics show BCE trades below historical and peer averages, suggesting ~25% upside potential over the next 2-3 years, excluding organic growth.

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced the first patient was dosed at The Ohio …

Selection underscores QuickLogic's ability to deliver flexible, silicon-proven IP that reduces ASIC risk and shortens design cycles for commercial applications SAN JOSE, Calif. , Nov. 18, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a developer of embedded FPGA (eFPGA) Hard IP and ruggedized FPGAs, announced today that its eFPGA Hard IP was selected by Chipus for a high performance data center production ASIC that will be fabricated on an industry-proven 12 nm process technology.

Investors still believe in tech. But it worries them as well.

Making its debut on 09/12/2016, smart beta exchange traded fund Fidelity Value Factor ETF (FVAL) provides investors broad exposure to the Style Box - Large Cap Value category of the market.

The First Trust Capital Strength ETF (FTCS) was launched on July 6, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Blend segment of the US equity market.

The Invesco Equal Weight 0-30 Year Treasury ETF (GOVI) made its debut on 10/11/2007, and is a smart beta exchange traded fund that provides broad exposure to the Government Bond ETFs category of the market.

The Invesco QQQ (QQQ) was launched on March 10, 1999, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Growth segment of the US equity market.

The First Trust Mid Cap Growth AlphaDEX ETF (FNY) was launched on 04/19/2011, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Mid Cap Growth category of the market.

Designed to provide broad exposure to the Large Cap Growth segment of the US equity market, the iShares Top 20 U.S. Stocks ETF (TOPT) is a passively managed exchange traded fund launched on October 23, 2024.

Launched on January 27, 2004, the Vanguard Large-Cap ETF (VV) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Blend segment of the US equity market.

Making its debut on 04/21/2006, smart beta exchange traded fund Vanguard Dividend Appreciation ETF (VIG) provides investors broad exposure to the Style Box - Large Cap Blend category of the market.

Making its debut on 04/15/2015, smart beta exchange traded fund State Street SPDR MSCI USA StrategicFactors ETF (QUS) provides investors broad exposure to the Style Box - Large Cap Blend category of the market.

The head of Google's parent company Alphabet warned that every company would be impacted if the AI bubble were to burst, in an interview to the BBC.

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Quanex Building Products Corporation (“Quanex” or “the Company”) (NYSE: NX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of NX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.